Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
Katie A ParselsKeri A MastroJeffrey M SteeleStephen J ThomasWesley D KufelPublished in: The Journal of antimicrobial chemotherapy (2021)
Cefiderocol is a novel siderophore cephalosporin that forms a complex with extracellular free ferric iron, which leads to transportation across the outer cell membrane to exert its bactericidal activity through cell wall synthesis inhibition. This pharmacological property has rendered cefiderocol active against several clinically relevant MDR Gram-negative bacteria as evidenced by several in vitro and in vivo studies. Cefiderocol was first approved by the US FDA on 14 November 2019 for the treatment of complicated urinary tract infections. On 28 September 2020, cefiderocol was approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. The FDA-approved indications are based on clinical data from the APEKS-cUTI, APEKS-NP and CREDIBLE-CR trials. In APEKS-cUTI, cefiderocol demonstrated non-inferiority to imipenem/cilastatin for the treatment of complicated urinary tract infection caused by MDR Gram-negative bacteria. In APEKS-NP, cefiderocol demonstrated non-inferiority to meropenem for treatment of nosocomial pneumonia. However, in CREDIBLE-CR, higher all-cause mortality was observed with cefiderocol compared with best available therapy for the treatment of severe infections caused by Gram-negative bacteria, primarily in the subset of patients with Acinetobacter spp. infections. Several case reports/series have demonstrated clinical success with cefiderocol for a variety of severe infections. The purpose of this article is to review available data on the mechanism of action, in vitro and in vivo data, pharmacokinetics, pharmacodynamics, susceptibility testing, efficacy and safety of cefiderocol to address its role in therapy.
Keyphrases
- gram negative
- multidrug resistant
- acinetobacter baumannii
- drug resistant
- urinary tract infection
- klebsiella pneumoniae
- intensive care unit
- stem cells
- machine learning
- mesenchymal stem cells
- staphylococcus aureus
- replacement therapy
- big data
- bone marrow
- extracorporeal membrane oxygenation
- drug induced
- acute respiratory distress syndrome
- methicillin resistant staphylococcus aureus